



## **PRESS RELEASE**

### **Crucell Announces Completion of Acquisition of SBL Vaccin AB**

**Leiden, The Netherlands, November 23, 2006** – Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that it has completed the acquisition of SBL Vaccin AB.

#### **About Crucell**

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6<sup>®</sup> production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Korea and the US. The Company employs about 900 people. For more information, please visit [www.crucell.com](http://www.crucell.com).

#### **Forward-looking statements**

*This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on July 6, 2006, and the section entitled "Risk Factors". The Company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).*

#### **For further information please contact:**

##### **Crucell N.V.**

Leonard Kruimer  
Chief Financial Officer  
Tel. +31 (0)71 524 8722  
[l.kruimer@crucell.com](mailto:l.kruimer@crucell.com)

Paul Vermeij  
Director Investor Relations and  
Corporate Communications  
Tel. +31 (0)71 524 8718  
[p.vermeij@crucell.com](mailto:p.vermeij@crucell.com)